Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics

Hepion Pharmaceuticals, Inc.

Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.
Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.
Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.